Cargando…

P19-11. Generation of virus-like particles expressing different HIV-1 glycoproteins for induction of broadly neutralizing antibodies

Detalles Bibliográficos
Autores principales:	Visciano, M, Tagliamonte, M, Tornesello, M, Lopalco, L, Buonaguro, F, Buonaguro, L
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767839/ http://dx.doi.org/10.1186/1742-4690-6-S3-P331

Ejemplares similares

P12-03. Generation of novel recombinant HIV-1 glycoproteins for expression on virus like particles
por: Tagliamonte, M, et al.
Publicado: (2009)

Effects of adjuvants on IgG subclasses elicited by virus-like Particles
por: Visciano, Maria Luisa, et al.
Publicado: (2012)

Virus-like Particles as Preventive and Therapeutic Cancer Vaccines
por: Tornesello, Anna Lucia, et al.
Publicado: (2022)

HPV monitoring in kidney transplanted patients
por: Buonaguro, Franco M, et al.
Publicado: (2012)

Structured particles for antigen presentation
por: Buonaguro, L, et al.
Publicado: (2006)

A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women
por: Tornesello, ML, et al.
Publicado: (2009)

Nanoparticles to Improve the Efficacy of Peptide-Based Cancer Vaccines
por: Tornesello, Anna Lucia, et al.
Publicado: (2020)

Genetic and phylogenetic evolution of HIV-1 in a low subtype heterogeneity epidemic: the Italian example
por: Buonaguro, Luigi, et al.
Publicado: (2007)

Conformational HIV-1 Envelope on particulate structures: a tool for chemokine coreceptor binding studies
por: Tagliamonte, Maria, et al.
Publicado: (2011)

SARS-CoV-2 RNA polymerase as target for antiviral therapy
por: Buonaguro, Luigi, et al.
Publicado: (2020)

Cellular prognostic markers in hepatitis-related hepatocellular carcinoma
por: Petrizzo, A., et al.
Publicado: (2018)

Neutralizing antibodies elicited in rabbits by patient-derived Env trimer immunization
por: Heyndrickx, L, et al.
Publicado: (2012)

Prediction of individual immune responsiveness to a candidate vaccine by a systems vaccinology approach
por: Petrizzo, Annacarmen, et al.
Publicado: (2014)

Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation
por: Aricò, Eleonora, et al.
Publicado: (2005)

V5 region in the HIV-1 envelope glycoprotein determines viral sensitivity to the broadly neutralizing monoclonal antibody VRC01
por: Guo, D, et al.
Publicado: (2012)

Molecular and phylogenetic analysis of HIV-1 variants circulating among injecting drug users in Mashhad-Iran
por: Naderi, HR, et al.
Publicado: (2006)

Systems Biology Approach for Cancer Vaccine Development and Evaluation
por: Circelli, Luisa, et al.
Publicado: (2015)

Systemic administration of a broadly-neutralizing IgG antibody to generate HIV-neutralization responses in breast milk
por: Fouda, GG, et al.
Publicado: (2012)

Cell Surface Proteins in Hepatocellular Carcinoma: From Bench to Bedside
por: Siracusano, Gabriel, et al.
Publicado: (2020)

Molecular mimicry and cancer vaccine development
por: Tagliamonte, Maria, et al.
Publicado: (2023)

P05-03. The use of immune complexes to enhance antibody responses against neutralizing epitopes on HIV envelope
por: Hioe, CE, et al.
Publicado: (2009)

Somatic mutations of STK11 gene in human papillomavirus positive and negative penile cancer
por: Annunziata, Clorinda, et al.
Publicado: (2013)

Molecular mimicry between tumor associated antigens and microbiota-derived epitopes
por: Ragone, Concetta, et al.
Publicado: (2022)

Characterization of humoral responses to soluble trimeric HIV gp140 from a clade A Ugandan field isolate
por: Visciano, Maria Luisa, et al.
Publicado: (2013)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

High Somatic Mutation and Neoantigen Burden Do Not Correlate with Decreased Progression-Free Survival in HCC Patients not Undergoing Immunotherapy
por: Mauriello, Angela, et al.
Publicado: (2019)

150 Carcinogenesis of HPV
por: Buonaguro, FM, et al.
Publicado: (2014)

Role of TP53 polymorphisms in sub-Saharan mucosal cancers
por: Buonaguro, Franco M, et al.
Publicado: (2010)

Recognition and penetration of the HIV-1 Env glycan shield by potent broadly neutralizing antibodies
por: Julien, J, et al.
Publicado: (2012)

HIV p24 as Scaffold for Presenting Conformational HIV Env Antigens
por: Tagliamonte, Maria, et al.
Publicado: (2012)

Functional characterization of biodegradable nanoparticles as antigen delivery system
por: Petrizzo, A., et al.
Publicado: (2015)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

HLA Does Not Impact on Short-Medium-Term Antibody Response to Preventive Anti-SARS-Cov-2 Vaccine
por: Ragone, Concetta, et al.
Publicado: (2021)

New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology
por: Tornesello, Anna Lucia, et al.
Publicado: (2017)

Eliciting broadly neutralizing antibodies against HIV-1 that target gp41 MPER
por: Han, D, et al.
Publicado: (2012)

Long-term memory T cells as preventive anticancer immunity elicited by TuA-derived heteroclitic peptides
por: Mauriello, Angela, et al.
Publicado: (2021)

Broad and potent neutralization of HIV-1 by human-llama fusion antibodies derived from immunized llamas
por: McCoy, LE, et al.
Publicado: (2012)

P04-51 LB. The epitopes of two newly identified broad and potent neutralizing antibodies, PG9 and PG16
por: Walker, L, et al.
Publicado: (2009)

P11-14. Analysis of mucosal antibodies in genital fluids of HIV seropositive subjects from Cambodian and Italian cohorts
por: Lopalco, L, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_01efe2l35uss6vr980pd5qnnua